Sequent Scientific Limited Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2023
February 13, 2024 at 10:24 am EST
Share
Sequent Scientific Limited reported earnings results for the third quarter and nine months ended December 31, 2023. For the third quarter, the company reported sales was INR 3,293.59 million compared to INR 3,753.13 million a year ago. Revenue was INR 3,338.77 million compared to INR 3,781.76 million a year ago. Net income was INR 82.68 million compared to net loss of INR 88.69 million a year ago. Basic earnings per share from continuing operations was INR 0.33 compared to basic loss per share from continuing operations of INR 0.36 a year ago. Diluted earnings per share from continuing operations was INR 0.33 compared to diluted loss per share from continuing operations of INR 0.36 a year ago.
For the nine months, sales was INR 10,085.34 million compared to INR 10,542.41 million a year ago. Revenue was INR 10,154.93 million compared to INR 10,588.94 million a year ago. Net loss was INR 349.58 million compared to INR 275.85 million a year ago. Basic loss per share from continuing operations was INR 1.41 compared to INR 1.11 a year ago. Diluted loss per share from continuing operations was INR 1.41 compared to INR 1.11 a year ago.
SeQuent Scientific Limited is an India-based animal health company. The Company provides a wide range of animal health products, including finished dose formulations, active pharmaceutical ingredients (APIs), as well as analytical services. The Company operates through the pharmaceuticals segment. The Company is focused on various therapies, such as targeted are anthelmintics (endo and ecto parasiticides), anti-protozoals, nutraceuticals, nonsteroidal anti-inflammatory drugs (NSAIDs), anti-infectives and dermatology. It is specialized in analytical and bio analytical services to support the API, pharmaceutical, personal care and nutraceutical companies. It provides analytical solutions, including method validation, stability, microbiology for APIs and finished products in a variety of dosage forms as per pharmacopoeia monographs, customer developed methods or in-house method development. Its subsidiaries include Alivira Animal Health Limited and SeQuent Research Limited.